Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 148, Issue 4, Pages 1014-1026Publisher
WILEY
DOI: 10.1002/ijc.33312
Keywords
circulating tumor DNA; colorectal cancer; prognosis; recurrence
Categories
Funding
- Victorian Cancer Agency Clinical Research Fellowship [CRF14007]
- National Institutes of Health [P50-CA062924, CA06973, CA176828, CA210170]
- John Templeton Foundation
Ask authors/readers for more resources
Studies have shown that postoperative ctDNA analysis is prognostically significant in nonmetastatic CRC patients, with higher predictive accuracy for recurrence compared to clinicopathologic risk factors, and increasing mutant allele frequency (MAF) further stratifying recurrence risk.
Studies in multiple solid tumor types have demonstrated the prognostic significance of ctDNA analysis after curative intent surgery. A combined analysis of data across completed studies could further our understanding of circulating tumor DNA (ctDNA) as a prognostic marker and inform future trial design. We combined individual patient data from three independent cohort studies of nonmetastatic colorectal cancer (CRC). Plasma samples were collected 4 to 10 weeks after surgery. Mutations in ctDNA were assayed using a massively parallel sequencing technique called SafeSeqS. We analyzed 485 CRC patients (230 Stage II colon, 96 Stage III colon, and 159 locally advanced rectum). ctDNA was detected after surgery in 59 (12%) patients overall (11.0%, 12.5% and 13.8% for samples taken at 4-6, 6-8 and 8-10 weeks;P= .740). ctDNA detection was associated with poorer 5-year recurrence-free (38.6% vs 85.5%;P < .001) and overall survival (64.6% vs 89.4%;P < .001). The predictive accuracy of postsurgery ctDNA for recurrence was higher than that of individual clinicopathologic risk features. Recurrence risk increased exponentially with increasing ctDNA mutant allele frequency (MAF) (hazard ratio, 1.2, 2.5 and 5.8 for MAF of 0.1%, 0.5% and 1%). Postsurgery ctDNA was detected in 3 of 20 (15%) patients with locoregional and 27 of 60 (45%) with distant recurrence (P= .018). This analysis demonstrates a consistent long-term impact of ctDNA as a prognostic marker across nonmetastatic CRC, where ctDNA outperforms other clinicopathologic risk factors and MAF further stratifies recurrence risk. ctDNA is a better predictor of distant vs locoregional recurrence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available